Here is a quick snapshot of the top 10 most read (and shared) stories we published in June. Our ranking is in ascending order, with the most popular story at the end of this post.
Industry vets launch mission-driven alts firm
With the backing of Invesco, finance veterans Colin Meadows, Kenneth Saffold and Brian Morris have launched o15 Capital Partners, an Atlanta-based firm dedicated to providing capital to companies led by and servicing undercapitalized entrepreneurs and communities. The firm’s new fund o15 Emerging America Credit Opportunities Fund LP will invest in a more diverse economy through … Continue reading
Florida adds multiple alts strategies
The $253 billion Florida State Board of Administration has added several managers across its alternative investment programs with another $676 million in new mandates as of late. Much of the capital went to private equity with $350 million in allocations to growth and buyout firms in which Florida has invested previously. The allocations were recommended … Continue readingFlorida adds multiple alts strategies
Hamilton Lane invests in alts RIA platform CAIS
Hamilton Lane has made a strategic investment in CAIS, an alternative investment platform that is used by 5,300 unique advisor firms/teams who oversee more than $2.5 trillion in network assets. Since inception CAIS has facilitated more than $17 billion in transaction volume and with the most recent financing now has an enterprise valuation exceeding $1.1 … Continue reading
Cinctive builds out macro strategy
New York hedge fund Cinctive Capital Management appointed macro investing veteran and former Millennium portfolio manager Giles Coppel as its macro chief investment officer as the firm expands its macro platform with several other senior hires. Coppell focused on global macro strategy at Millennium and prior to that managed his own firm Phillimore Investments. Prior … Continue reading
Headwinds and opportunities in biopharma
Although the biopharmaceutical sector is facing major headwinds due to a tough regulatory and political environment, COVID, inflation, rising interest rates, geopolitical stability, overcapitalized innovation, poor managerial execution, and more, I believe the biopharmaceutical sector offers investment opportunities in a select number of private and public companies across all cap sizes in the U.S., EU, … Continue reading
Benefit Street Partners assets double with Franklin’s Alcentra purchase
Franklin Templeton has agreed to acquire BNY Alcentra Group Holdings from BNY Mellon in a deal that will effectively double the assets of its U.S. alternative credit specialist Benefit Street Partners and expand its presence in Europe. One of the largest European credit and private debt managers, Alcentra has $38 billion in assets across senior .